Novartis Foundation Symposium no. 223: Insect-Plant Interactions (Novartis Foundation Symposia)
The IN VIVO Blog (Free subscription) | 20/11/2009
People, we seriously need to talk about Eggo Waffles. But first, a dearth of meaty deals this week has us thinking more about Bristol-Myers Squibb's share-swap/buyback/spin-off of its nutritionals unit Mead Johnson. We tried to make the point earlier this week that Bristol's move was too focused on short-term gain. Others have pointed out to us that without some sort of short-term gain to appease...
ireland.com (Free subscription) | 20/11/2009
In a change of tack, Europe's drugs watchdog said today that giving a single dose of GlaxoSmithKline's Pandemrix or Novartis's Focetria swine flu vaccines would suffice for most people.
Daily News Analysis (Free subscription) | 19/11/2009
Dan Vasella, the chief executive of Swiss firm Novartis, which has been struggling for the last five years to secure the patent rights in India on Glivec.
Fiercebiotech (Free subscription) | 19/11/2009
The FDA's Vaccines and Related Biological Products Advisory Committee today will determine whether Protein Sciences' flu vaccine FluBlok, which can be produced in less than two months by inserting flu genes into an insect virus and growing it in caterpillar ovary cells, warrants approval. FluBlok can be produced in a third of the time it takes larger drugmakers, including Sanofi-Aventis, GlaxoSmithKline...
Business Wire (Free subscription) | 18/11/2009
NASHVILLE, Tenn.--(BUSINESS WIRE)--Through a pioneering program – the Continued Access Program – the Dispensary of Hope is opening access to a consistent supply of critical medications to tens of thousands of Tennessee’s uninsured citizens. The program is a partnership between the Dispensary of Hope and three leading pharmaceutical companies including Novartis, Merck and AstraZeneca....
Daily Tech (Free subscription) | 18/11/2009
Biotech company Novartis discovered half of its H1N1 vaccine may be enough to boost the receiver's immunity
Glick Report (Free subscription) | 18/11/2009
In another First on FOX Business interview, I had the chance to sit down with Dr. Daniel Vasella, CEO of Novartis. Novartis is one of only a handful of companies that's in the business of producing vaccines, and the production of the swine flu vaccine has kept them working round-the-clock. They have already delivered about 19 [...]
SeekingAlpha.com (Free subscription) | 17/11/2009
VFC submits: It was a quick rise to the $2.40 level for shares of Titan Pharmaceuticals ( TTNP.PK ), as it finally looks like the stock is starting to trade towards its potential. With the heavyweight Novartis ( NVS ) set to commercially launch Fanapt early next year, the schizophrenia drug could quickly gain a foothold in a huge market ($14 billion) that has the lowest selling product raking in over...
Midas Oracle .ORG (Free subscription) | 17/11/2009
Midas Oracle = About + Archives + Authors + Best + Contact + Information Technology + Links + Probabilistic Predictions + Post-Mortem Predictions + Prediction Exchanges + Prediction Software + Publish Your Post + How To Publish Share This: Midas Oracle = About + Archives + Authors + Best + Contact + Information Technology + Links + Probabilistic Predictions + Post-Mortem Predictions + Prediction Exchanges...
MSNBC.com: Infectious Diseases (Free subscription) | 17/11/2009
Pharmaceutical maker Novartis said Tuesday a U.S. study suggests that half a dose of its swine flu vaccine may be sufficient to protect people from the virus and could allow many more to be immunized with current supplies. Immunization - Swine influenza - United States - Health - Novartis
Fiercebiotech (Free subscription) | 17/11/2009
Belgium's UCB is reengineering some of its research operations as it trims two percent of its global workforce. Its research division NewMedicines is being downsized, with 174 positions at its Braine-l'Alleud site in Belgium and 44 positions in Slough, England on the chopping block. R&D isn't the only division to be affected by the cuts. It is streamlining support services, industrial development...
Miami Herald (Free subscription) | 17/11/2009
Pharmaceutical maker Novartis AG said Tuesday a U.S. clinical study suggests that half a dose of its swine flu vaccine may be sufficient to protect people from the virus and could allow many more to be immunized with current supplies.
Joseph Kim, MD, MPH (Free subscription) | 17/11/2009
The FDA approved the fifth vaccine for protection against the 2009 H1N1 influenza virus. The vaccine is manufactured by ID Biomedical Corp. of Quebec, Canada, owned by GlaxoSmithKline PLC. So, here's a list of the current injectable H1N1 vaccines: Influenza A (H1N1) 2009 Monovalent Vaccine (CSL Limited) Influenza A (H1N1) 2009 Monovalent Vaccine (ID Biomedical Corporation of Quebec) Influenza A (H1N1)...
ProjectDisaster (Free subscription) | 17/11/2009
http://www.novartis.com/newsroom/media-releases/en/2009/1355007.shtml Novartis receives approval in Switzerland for Celtura®, a cell culture-based Influenza A(H1N1) pandemic vaccine Swissmedic approval allows Novartis to begin shipments of Celtura to Switzerland, providing supplies of A(H1N1) vaccine immediately Approvals in Germany and Switzerland demonstrate expanded adoption of new cell culture...
Health - The Post Chronicle (Free subscription) | 17/11/2009
A U.S. clinical study suggests that just half a dose of the Novartis AG H1N1 vaccine may be enough to generate a protective immune response, the Swiss drugmaker said on Tuesday....
Videos